Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Teleflex (TFX)

Teleflex names Jason Weidman CEO, effective June 8, 2026; Randle stays on board

Neutral Impact 4 of 5 leadership Written later

Teleflex said Jason Weidman, previously a senior leader at Medtronic, will become President and Chief Executive Officer on June 8, 2026, succeeding interim CEO Stuart Randle, who will remain on the Board. Weidman is also expected to join the Board as a director at that time. The filing's compensation terms include a $1 million base salary and a $7 million sign-on restricted stock grant, which shareholders may track in future proxy and SEC filings.

Key points

  • Start date is June 8, 2026; Weidman is expected to join the Board as a director on that date.
  • Offer letter dated April 26, 2026 provides a $1 million base salary and a target annual bonus of 125% of base salary.
  • Sign-on restricted stock grant has a grant date fair value of $7 million; stock options have a grant date fair value of $1 million.
  • Chairman Stephen Klasko said the appointment follows the divestitures and the planned $1 billion share buyback and $800 million debt paydown.

The filing

CompanyTeleflex (TFX)
Form8-K, current report
Filed with the SECApr 30, 2026, 4:30 PM ET
Accession number0000096943-26-000042

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.